These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Moxifloxacin, a new antibiotic designed to treat community-acquired respiratory tract infections: a review of microbiologic and pharmacokinetic-pharmacodynamic characteristics. Nightingale CH Pharmacotherapy; 2000 Mar; 20(3):245-56. PubMed ID: 10730681 [TBL] [Abstract][Full Text] [Related]
9. Concentrations of garenoxacin in plasma, bronchial mucosa, alveolar macrophages and epithelial lining fluid following a single oral 600 mg dose in healthy adult subjects. Andrews J; Honeybourne D; Jevons G; Boyce M; Wise R; Bello A; Gajjar D J Antimicrob Chemother; 2003 Mar; 51(3):727-30. PubMed ID: 12615879 [TBL] [Abstract][Full Text] [Related]
10. Rifampicin concentrations in bronchial mucosa, epithelial lining fluid, alveolar macrophages and serum following a single 600 mg oral dose in patients undergoing fibre-optic bronchoscopy. Ziglam HM; Baldwin DR; Daniels I; Andrew JM; Finch RG J Antimicrob Chemother; 2002 Dec; 50(6):1011-5. PubMed ID: 12461025 [TBL] [Abstract][Full Text] [Related]
12. [In vitro activity of moxifloxacin against respiratory pathogens in Latin America]. López H; Sader H; Amábile C; Pedreira W; Muñoz Bellido JL; García Rodríguez JA; Rev Esp Quimioter; 2002 Dec; 15(4):325-34. PubMed ID: 12587037 [TBL] [Abstract][Full Text] [Related]
13. Moxifloxacin sensitivity of respiratory pathogens in the United Kingdom. Dorai-John T; Thomson CJ; Amyes SG J Chemother; 2002 Feb; 14(1):19-24. PubMed ID: 11892894 [TBL] [Abstract][Full Text] [Related]
14. Penetration of sparfloxacin and ciprofloxacin into alveolar macrophages, epithelial lining fluid, and polymorphonuclear leucocytes. Schüler P; Zemper K; Borner K; Koeppe P; Schaberg T; Lode H Eur Respir J; 1997 May; 10(5):1130-6. PubMed ID: 9163658 [TBL] [Abstract][Full Text] [Related]
15. [National multicenter study of the in vitro activity of moxifloxacin against respiratory tract pathogens. Spanish Study Group on Moxifloxacin]. Loza E; Morosini M; Negri MC; Almaraz F; Cantón R; Baquero F Rev Esp Quimioter; 2000 Mar; 13(1):37-43. PubMed ID: 10855023 [TBL] [Abstract][Full Text] [Related]
16. Comparative penetration of selected fluoroquinolones into respiratory tract fluids and tissues. Wise R Am J Med; 1991 Dec; 91(6A):67S-70S. PubMed ID: 1662897 [TBL] [Abstract][Full Text] [Related]
17. Comparative pharmacodynamics of garenoxacin, gemifloxacin, and moxifloxacin in community-acquired pneumonia caused by Streptococcus pneumoniae: a Monte Carlo simulation analysis. Noreddin AM; Reese AA; Ostroski M; Hoban DJ; Zhanel GG Clin Ther; 2007 Dec; 29(12):2685-9. PubMed ID: 18201584 [TBL] [Abstract][Full Text] [Related]
18. The penetration of rufloxacin into sites of potential infection in the respiratory tract. Wise R; Andrews J; Imbimbo BP; Greaves I; Honeybourne D J Antimicrob Chemother; 1993 Dec; 32(6):861-6. PubMed ID: 8144426 [TBL] [Abstract][Full Text] [Related]
19. Single- and multiple-dose pharmacokinetics of oral moxifloxacin and clarithromycin, and concentrations in serum, saliva and faeces. Burkhardt O; Borner K; Stass H; Beyer G; Allewelt M; Nord CE; Lode H Scand J Infect Dis; 2002; 34(12):898-903. PubMed ID: 12587622 [TBL] [Abstract][Full Text] [Related]
20. Serum and prostatic tissue concentrations of moxifloxacin in patients undergoing transurethral resection of the prostate. Wagenlehner FM; Lunz JC; Kees F; Wieland W; Naber KG J Chemother; 2006 Oct; 18(5):485-9. PubMed ID: 17127224 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]